Head to Head Comparison: Repare Therapeutics (NASDAQ:RPTX) and Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Repare Therapeutics (NASDAQ:RPTX) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Provectus Biopharmaceuticals shares are owned by institutional investors. 11.5% of Repare Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Provectus Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repare Therapeutics	N/A	-78.12%	-67.11%
Provectus Biopharmaceuticals	-815.81%	N/A	-644.80%

Analyst Ratings

This is a summary of recent ratings and price targets for Repare Therapeutics and Provectus Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repare Therapeutics	0	2	2	0	2.50
Provectus Biopharmaceuticals	0	0	0	0	0.00

Repare Therapeutics currently has a consensus target price of $4.50, indicating a potential upside of 200.00%. Given Repare Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Repare Therapeutics is more favorable than Provectus Biopharmaceuticals.

Earnings & Valuation

This table compares Repare Therapeutics and Provectus Biopharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repare Therapeutics	$53.48 million	1.20	-$84.69 million	($3.01)	-0.50
Provectus Biopharmaceuticals	$620,000.00	62.30	-$4.76 million	N/A	N/A

Provectus Biopharmaceuticals has lower revenue, but higher earnings than Repare Therapeutics.

Volatility & Risk

Repare Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Summary

Repare Therapeutics beats Provectus Biopharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Repare Therapeutics

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.